Novavax Inc Revenue Growth Rates (NVAX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Novavax inc   (NASDAQ: NVAX)
 

NVAX's Revenue Growth by Quarter and Year

Novavax Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NVAX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 56.70
1st Quarter March 139.51
FY 196.21

NVAXs Annual Revenue
Novavax Inc 's Revenue in the fiscal year 2025 $ 1,123.48 millions
Novavax Inc 's Revenue in the fiscal year 2024 $ 682.16 millions
Novavax Inc 's Revenue in the fiscal year 2023 $ 983.71 millions
Novavax Inc 's Revenue in the fiscal year 2022 $ 1,981.87 millions
Novavax Inc 's Revenue in the fiscal year 2021 $ 1,146.29 millions




NVAX Revenue second quarter 2026 Y/Y Growth Comment
Novavax Inc reported drop in Revenue in the second quarter 2026 by -76.3% to $ 56.70 millions, from the same quarter in 2025.
The fall in the second quarter 2026 Novavax Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 216.95%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 47 other companies have achieved higher Revenue growth. While Novavax Inc ' s Revenue meltdown of -76.3% ranks overall at the positon no. 3310 in the second quarter 2026.


NVAX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 66.62 % -69.69 % -18.48 %
3rd Quarter September - -16.64 % -54.81 % -74.54 %
2nd Quarter June -76.3 % -42.42 % -2.11 % 128.27 %
1st Quarter March -79.07 % 610.27 % 15.95 % -88.5 %
FY   - 64.7 % -30.65 % -

Financial Statements
Novavax Inc 's second quarter 2026 Revenue $ 56.70 millions NVAX's Income Statement
Novavax Inc 's second quarter 2025 Revenue $ 239.24 millions Quarterly NVAX's Income Statement


NVAX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 108.86 % 4.5 % 55.81 %
3rd Quarter September - -70.55 % -79.66 % -55.94 %
2nd Quarter June -59.36 % -64.11 % 342.66 % 424.31 %
1st Quarter March -5.19 % 654.91 % -67.78 % -77.35 %
FY (Year on Year)   - 64.7 % -30.65 % -


Back to NVAX Growth rate Comparisons >> Back to NVAX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #440
Overall #3310

Revenue Y/Y Growth Statistics
High Average Low
4991.93 % 216.95 % -61.64 %
(Mar 31 2021)   (Jun 30 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #440
Overall #3310
Revenue Y/Y Growth Statistics
High Average Low
4991.93 % 216.95 % -61.64 %
(Mar 31 2021)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Novavax Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
952.35 % 57.1 % -79.66 %
(Jun 30 2020)  


NVAX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Novavax Inc disclosed fall in Revenue from the first quarter by -59.36% to $ 56.70 millions, from $ 139.51 millions achived in the previous reporting period.

But that's not important problem, as Novavax Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 57 other companies have achieved higher Revenue quarter on quarter growth. While Novavax Inc 's Revenue growth quarter on quarter, overall rank is 3736.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #58
Healthcare Sector #544
Overall #3736
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #58
Healthcare Sector #544
Overall #3736
Revenue Q/Q Growth Statistics
High Average Low
952.35 % 57.1 % -79.66 %
(Jun 30 2020)  


NVAX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Novavax Inc disclosed fall in Revenue from the first quarter by -59.36% to $ 56.70 millions, from $ 139.51 millions achived in the previous reporting period.

But that's not important problem, as Novavax Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 57 other companies have achieved higher Revenue quarter on quarter growth. While Novavax Inc 's Revenue growth quarter on quarter, overall rank is 3736.


Novavax Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 413.80 $ 596.34 $ 1,123.48 $ 1,064.65 $ 1,078.72
Y / Y Revenue Growth (TTM) -61.64 % -52.48 % 64.69 % 20.27 % 9.22 %
Year on Year Revenue Growth Overall Ranking # 1605 # 142 # 2327 # 2251 # 1437
Seqeuential Revenue Change (TTM) -30.61 % -46.92 % 5.53 % -1.3 % -14.04 %
Seq. Revenue Growth (TTM) Overall Ranking # 3310 # 23 # 2289 # 2158 # 1920


Cumulative Revenue growth Comment
Novavax Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -61.64% year on year, at Jun 30 2026 compare to the -52.48% decrease at Mar 31 2026. If the Novavax Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $414 millions.

In the Healthcare sector 259 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 142 to 1605.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 260
Overall # 1605

Revenue TTM Y/Y Growth Statistics
High Average Low
4991.93 %
 216.95 %
-61.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 440
S&P 500 # 3310
Cumulative Revenue growth Comment
Novavax Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -61.64% year on year, at Jun 30 2026 compare to the -52.48% decrease at Mar 31 2026. If the Novavax Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $414 millions.

In the Healthcare sector 259 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 142 to 1605.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 260
Overall # 1605

Revenue TTM Y/Y Growth Statistics
High Average Low
4991.93 %
216.95 %
-61.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 440
S&P 500 # 3310




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NVAX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Novavax Inc Revenue Growth Rates (NVAX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Novavax Inc (CIK 1000694).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001000694-26-000018
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Novavax Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.